Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9Q2B6)

Drug Name
GS-9876 Drug Info
Synonyms
XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr
Indication
Disease Entry ICD 11 Status REF
Cutaneous lupus erythematosus EB5Z Phase 2 [1]
Rheumatoid arthritis FA20 Phase 1 [2]
Cross-matching ID
PubChem CID
118161062
CAS Number
CAS 1800046-95-0
TTD Drug ID
DM9Q2B6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tyrosine-protein kinase SYK (SYK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fostamatinib DM6AUHV Immune thrombocytopenic purpura 3B64.13 Approved [3]
Fostamatinib disodium DM3274D Thrombocytopenia 3B64 Phase 3 [4]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [5]
TAK-659 DMJH3U0 Diffuse large B-cell lymphoma 2A81 Phase 2 [6]
GS-9973 DMKWCTR Acute myeloid leukaemia 2A60 Phase 2 [7]
Cevidoplenib DM9QU5G Rheumatoid arthritis FA20 Phase 2 [8]
HM43239 DMV1SDA Acute myeloid leukaemia 2A60 Phase 1/2 [9]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [10]
SKI-O-703 DMTSKXR Rheumatoid arthritis FA20 Phase 1 [2]
PRT6207 DMP5CLY Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase SYK (SYK) TTOU65C KSYK_HUMAN Inhibitor [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Company report (Portola Pharmaceuticals)
6 J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
7 An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
8 A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45.
9 Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
10 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
11 Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.